Clexio Biosciences

Executive Summary

Clexio Biosciences is a clinical-stage biotechnology company developing novel oral therapies for neuropsychiatric disorders, with a focus on major depressive disorder (MDD) and epilepsy. Its lead candidate, CLE-100, is an NMDA receptor antagonist being evaluated in Phase 2 trials for treatment-resistant depression, leveraging a validated mechanism to offer rapid-acting relief. The second candidate, CLE-043, is a KV7.2/3 potassium channel opener designed for epilepsy and MDD, with the potential to be a first-in-class therapy. Both programs aim to address significant unmet needs by providing fast-acting, disease-modifying oral agents. Clexio’s pipeline is built on strong scientific rationale, and the company is advancing its clinical programs with the goal of delivering differentiated treatments to patients.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for CLE-100 in MDD55% success
• Q4 2026Phase 1 results for CLE-043 in epilepsy50% success
• TBDStrategic partnership or financing announcement40% success